Top 12 From Cathie Wood's Q2 Portfolio
In this article, we will be taking a look at the top 12 from Cathie Wood's Q2 portfolio.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 9,727,531 | $564,683 | +4% | 3.33% |
| 2. | Armistice Capital Steven Boyd | 1,000,000 | $60,770 | -3% | 1.06% |
| 3. | 878,300 | $53,374 | +84% | 0.01% | |
| 4. | Renaissance Technologies Jim Simons | 568,700 | $34,560 | -20% | 0.04% |
| 5. | 515,900 | $31,351 | +10% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.95 | 27,461 | Large Shareholder | 5,380,940 | 2018-12-27 | Filing | |
| $24.89 | 12,737 | Large Shareholder | 5,353,479 | 2018-12-26 | Filing | |
| $24.97 | 53,655 | Large Shareholder | 5,340,742 | 2018-12-24 | Filing | |
| $23.18 | 11,742 | Large Shareholder | 5,287,087 | 2018-12-24 | Filing | |
| $22.91 | 2,603 | Large Shareholder | 5,275,345 | 2018-12-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64.97 | 1,800 | Officer, Director | 290,279 | 2022-09-28 | Filing | |
| $64.58 | 23,200 | Officer, Director | 292,079 | 2022-09-28 | Filing | |
| $67.64 | 163 | Officer, Director | 290,279 | 2022-08-29 | Filing | |
| $66.98 | 20,764 | Officer, Director | 290,442 | 2022-08-29 | Filing | |
| $66.14 | 4,073 | Officer, Director | 311,206 | 2022-08-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 133,154 | $8,091,770 | 0% | |
| 2. | 104,142 | $6,328,709 | 0.05% | |
| 3. | 29,800 | $1,810,946 | 0.01% | |
| 4. | 12,799 | $777,825 | 0.08% | |
| 5. | 6,628 | $403,000 | 0.16% |
News See All
Cathie Wood Dumped These 3 Stocks in July
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a Massachusetts-based genome editing company that develops novel genomic medicines using CRISPR/Cas9 technology for the treatment of ocular diseases.
Cathie Wood's Fund Starts to Rebound: 10 Stocks to Watch
In this article, we discuss 10 stocks to watch as Cathie Wood's fund starts to rebound.
Analysts Just Decreased Price Targets of These 5 Stocks
In this article, we discuss the 5 stocks that recently received price-target cuts from analysts.
Hedge Funds Love These 10 Undervalued Mid-Cap Stocks
In this article, we discuss the 10 undervalued mid-cap stocks that hedge funds love.
Cathie Wood's 5 Stock Picks for the Next 5 Years
In this article, we discuss Cathie Wood's 5 stock picks for the next 5 years.
10 Innovative Stocks in Cathie Wood's Portfolio That Failed to Impress
In this article, we discuss 10 innovative stocks in Cathie Wood’s portfolio that failed to impress.
5 Genomics Stocks in Cathie Wood's Portfolio That Are Underperforming
In this article, we discuss 5 genomics stocks in Cathie Wood’s portfolio that are underperforming.
Mario Gabelli is Selling These 10 Stocks
In this article, we discuss the 10 stocks that Mario Gabelli is selling.
Was The Smart Money Right About CRISPR Therapeutics AG (CRSP)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
